Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials - PubMed
6 hours ago
- #meta-analysis
- #MASLD
- #pharmacotherapy
- Tirzepatide and resmetirom significantly improved MASH resolution without worsening of fibrosis and reduced hepatic steatosis in patients with MASLD/MASH.
- All three agents (tirzepatide, lanifibranor, resmetirom) lowered serum aminotransferase levels, with lanifibranor and resmetirom also improving lipid profiles.
- Gastrointestinal adverse events were commonly reported across all treatments, potentially affecting tolerability, and further large-scale studies are needed due to limited trial numbers for some agents.